Rule 34

Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on Isotopically Enriched Forms of ALZ-801/Valiltramiprosate

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Professional Services, Health, Patent Law, Pharmaceutical, Neurology, Research, Genetics, Legal, Science, Clinical Trials, Comment, Patent, Patient, NDA, PTAB, Federal Circuit Court, Doctor of Philosophy, IPR, Prodrug, Rule 34, Pharmaceutical industry

The decision was affirmed without discussion by the Federal Circuit Court (Case No.

Key Points: 
  • The decision was affirmed without discussion by the Federal Circuit Court (Case No.
  • In 2020, Alzheon petitioned the Patent Trial and Appeal Board (PTAB) of the U.S. Patent Office (USPTO) to institute an Inter-Parties Review (IPR) of Risen’s U.S. Patent No.
  • Risen appealed the PTAB’s decision to the United States Court of Appeals for the Federal Circuit.
  • “Alzheon is pleased that the U.S. Federal Circuit affirmed the Patent Trial and Appeal Board’s decision to invalidate all claims of Risen’s patent.